ArticleOpen biology2013
Active regulator of SIRT1 is required for cancer cell survival but not for SIRT1 activity.
Article in Open biology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 28 citations in OpenAlex.
- Site-specific programming characterizes dynamic post-translational acetylation of histone H2B lysine 108 in mouse embryonic stem cells.Nature communications · 2026Article
- Transcriptional readthrough at Atf4 locus suppresses Rps19bp1 and impairs heart development.Cardiovascular research · 2026Article
- TROAP aggravates chemoresistance of colorectal cancer cells via lipogenesis by PI3K/Akt pathway and histone acetylation.Functional & integrative genomics · 2025Article
- Transcriptional Readthrough atbioRxiv : the preprint server for biology · 2025Article
- New insights into Sirt1: potential therapeutic targets for the treatment of cerebral ischemic stroke.Frontiers in cellular neuroscience · 2023Review
- Molecular Mechanism of Sirtuin 1 Modulation by the AROS Protein.International journal of molecular sciences · 2022Article
- Regulation of SIRT1 and Its Roles in Inflammation.Frontiers in immunology · 2022Review
- Article
- The Warburg effect as a therapeutic target for bladder cancers and intratumoral heterogeneity in associated molecular targets.Cancer science · 2021Article
- Sirtuins as Important Factors in Pathological States and the Role of Their Molecular Activity Modulators.International journal of molecular sciences · 2021Review
- Systematic Construction and Validation of an RNA-Binding Protein-Associated Prognostic Model for Acute Myeloid Leukemia.Frontiers in genetics · 2021Article
- CSAG2 is a cancer-specific activator of SIRT1.EMBO reports · 2020Article
- Sirtuin activators and inhibitors: Promises, achievements, and challenges.Pharmacology & therapeutics · 2018Review
- Using mitochondrial sirtuins as drug targets: disease implications and available compounds.Cellular and molecular life sciences : CMLS · 2016Review
- miR-34a inhibits cell proliferation in prostate cancer by downregulation of SIRT1 expression.Oncology letters · 2015Article
- BET Inhibition Upregulates SIRT1 and Alleviates Inflammatory Responses.Chembiochem : a European journal of chemical biology · 2015Article
- AROS Is a Significant Biomarker for Tumor Aggressiveness in Non-cirrhotic Hepatocellular Carcinoma.Journal of Korean medical science · 2015Article
- SIRT1 and stem cells: In the forefront with cardiovascular disease, neurodegeneration and cancer.World journal of stem cells · 2015Article
- Microrna expression signatures predict patient progression and disease outcome in pediatric embryonal central nervous system neoplasms.Journal of hematology & oncology · 2014Article
- WISP1: Clinical insights for a proliferative and restorative member of the CCN family.Current neurovascular research · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The NAD(+)-dependent deacetylase SIRT1 is involved in diverse cellular processes, and has also been linked with multiple disease states. Among these, SIRT1 expression negatively correlates with cancer survival in both laboratory and clinical studies. Active regulator of SIRT1 (AROS) was the first reported post-transcriptional regulator of SIRT1 activity, enhancing SIRT1-mediated deacetylation and downregulation of the SIRT1 target p53. However, little is known regarding the role of AROS in regulation of SIRT1 during disease. Here, we report the cellular and molecular effects of RNAi-mediated AROS suppression, comparing this with the role of SIRT1 in a panel of human cell lines of both cancerous and non-cancerous origins. Unexpectedly, AROS is found to vary in its modulation of p53 acetylation according to cell context. AROS suppresses p53 acetylation only following the application of cell damaging stress, whereas SIRT1 suppresses p53 under all conditions analysed. This supplements the original characterization of AROS but indicates that SIRT1 activity can persist following suppression of AROS. We also demonstrate that knockdown of AROS induces apoptosis in three cancer cell lines, independent of p53 activation. Importantly, AROS is not required for the viability of three non-cancer cell lines indicating a putative role for AROS in specifically promoting cancer cell survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.